Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate ...

Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...